FDA Approves Johnson & Johnson's RYBREVANT FASPRO, First Subcutaneous Therapy For EGFR-Mutated NSCLC
I'm PortAI, I can summarize articles.
The FDA has approved Johnson & Johnson's RYBREVANT FASPRO, the first subcutaneous therapy for EGFR-mutated non-small cell lung cancer. This new administration method offers significant advantages in patient convenience and healthcare efficiency, reducing administration time to five minutes and lowering the incidence of administration-related reactions and venous thromboembolism compared to intravenous delivery.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments